These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 15232793)
41. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157 [TBL] [Abstract][Full Text] [Related]
42. The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: a national survey. Martin CJ; Reams SM J Ren Nutr; 2003 Apr; 13(2):133-6. PubMed ID: 12671837 [TBL] [Abstract][Full Text] [Related]
43. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941 [TBL] [Abstract][Full Text] [Related]
44. Treatment of hyperphosphatemia, secondary hyperparathyroidism and hypocalcemia with calcium carbonate favorably modulates vaccination response in uremic rats. Hannula PM; Pörsti IH; Saha HH; Kalliovalkama J; Jolma PM; Kööbi P; Olander RM; Antonen JA Clin Nephrol; 2004 Jun; 61(6):406-12. PubMed ID: 15224804 [TBL] [Abstract][Full Text] [Related]
45. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients]. Kiss D; Battegay M; Meier C; Lyrer A Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655 [TBL] [Abstract][Full Text] [Related]
46. Calcium exposure and removal in chronic hemodialysis patients. Sigrist M; McIntyre CW J Ren Nutr; 2006 Jan; 16(1):41-6. PubMed ID: 16414440 [TBL] [Abstract][Full Text] [Related]
47. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Pflanz S; Henderson IS; McElduff N; Jones MC Nephrol Dial Transplant; 1994; 9(8):1121-4. PubMed ID: 7800211 [TBL] [Abstract][Full Text] [Related]
48. Multidisciplinary education approach to optimize phosphate control among hemodialysis patients. Chan MW; Cheah HM; Mohd Padzil MB Int J Clin Pharm; 2019 Oct; 41(5):1282-1289. PubMed ID: 31302884 [TBL] [Abstract][Full Text] [Related]
49. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients. Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741 [TBL] [Abstract][Full Text] [Related]
50. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients. Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559 [TBL] [Abstract][Full Text] [Related]
51. Hyperphosphatemia modestly retards parathyroid hormone suppression during calcitriol-induced hypercalcemia in normal and azotemic rats. Jara A; Chacón C; Felsenfeld AJ Nephron; 2002 Dec; 92(4):883-8. PubMed ID: 12399635 [TBL] [Abstract][Full Text] [Related]
52. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Hervás JG; Prados D; Cerezo S Kidney Int Suppl; 2003 Jun; (85):S69-72. PubMed ID: 12753270 [TBL] [Abstract][Full Text] [Related]
53. Correcting acidosis in hemodialysis: effect on phosphate clearance and calcification risk. Harris DC; Yuill E; Chesher DW J Am Soc Nephrol; 1995 Dec; 6(6):1607-12. PubMed ID: 8749687 [TBL] [Abstract][Full Text] [Related]
54. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Shigematsu T; Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540 [TBL] [Abstract][Full Text] [Related]
55. Long-term administration of calcium acetate efficiently controls severe hyperphosphataemia in haemodialysis patients. Hess B; Binswanger U Nephrol Dial Transplant; 1990; 5(8):630-2. PubMed ID: 23276001 [TBL] [Abstract][Full Text] [Related]
56. Dietary phosphate restriction in dialysis patients: a new approach for the treatment of hyperphosphataemia. Guida B; Piccoli A; Trio R; Laccetti R; Nastasi A; Paglione A; Memoli A; Memoli B Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):879-84. PubMed ID: 20609572 [TBL] [Abstract][Full Text] [Related]
57. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797 [TBL] [Abstract][Full Text] [Related]
58. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis. Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645 [TBL] [Abstract][Full Text] [Related]
60. Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations. Hutchison AJ; Were AJ; Boulton HF; Mawer EB; Laing I; Gokal R Nephron; 1996; 72(1):52-8. PubMed ID: 8903861 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]